This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Low Dose ColchiciNe on the InciDence of POAF (END-AFLD)

This study is not yet open for participant recruitment.
See Contacts and Locations
Verified January 2017 by Jordan Collaborating Cardiology Group
Information provided by (Responsible Party):
Jordan Collaborating Cardiology Group Identifier:
First received: January 4, 2017
Last updated: January 7, 2017
Last verified: January 2017
The prior End-AF study by the same group showed that 1 mg of colchicine didn't decrease the incidence of AF after cardiac surgery. The current study, End-AF Low Dose Study, will test 0.5 mg colchicine vs. placebo in preventing AF after cardiac surgery.

Condition Intervention Phase
Atrial Fibrillation Cardiac Surgery Colchicine Adverse Reaction Drug: Colchicine Drug: Placebo Oral Tablet Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Effect of Low Dose ColchiciNe on the InciDence of Atrial Fibrillation in Open Heart Surgery Patients

Resource links provided by NLM:

Further study details as provided by Jordan Collaborating Cardiology Group:

Primary Outcome Measures:
  • Atrial fibrillation [ Time Frame: Through study completion, an average of 1 week ]
    AF documented by EKG

Secondary Outcome Measures:
  • Side effects of colchicine [ Time Frame: Through study completion, an average of 1 week ]
    Gastrointestinal side effects

Estimated Enrollment: 1200
Study Start Date: March 2017
Estimated Study Completion Date: May 2020
Estimated Primary Completion Date: March 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Colchicine
Intervention by administering an active copmarator of 1 mg colchicine one day pre op and 0.5 mg daily after surgery until discharge
Drug: Colchicine
Colchicine will be given to open heart surgery patients
Other Name: Colcrys, Mitigare
Placebo Comparator: Placebo Oral Tablet
Identical tablet (placebo) administered in a similar way as that in the active comparator arm
Drug: Placebo Oral Tablet
Placebo Oral Tablet will be given to open heart surgery patients according to randomization
Other Name: Placebo

Detailed Description:

AF after cardiac surgery leads to excess mortality and morbidity. Colchicine was used in several studies to lower the incidence AF but the results were generally disappointing. There was no benefit in reducing AF and there was a high incidence of GI side effects especially diarrhea, often leading to stopping the medication. However, a recently published meta-analysis showed that colchicine reduced AF, but again warned of the high incidence of GI side effects. The maintenance dose of colchicine used in these studies was 1 mg daily it is hypothesized that low dose colchicine (0.5 not 1 mg colchicine) might lower AF after cardiac surgery without the prohibitive GI side effects Patients will be randomized to colchicine vs. placebo started the day before surgery and continued until hospital discharge.

The primary efficacy endpoint will be the incidence of AF. The primary safety endpoint will be the GI side effects


Ages Eligible for Study:   18 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All patients aged 18 years or above undergoing elective cardiac surgery.
  • Sinus rhythm and no previous AF
  • Agreed to sign informed consent.

Exclusion Criteria:

  • Known severe liver disease or current transaminases >1.5 times the upper normal limit
  • Current serum creatinine >2.5 mg/dL
  • Known myopathy or elevated baseline preoperative creatine kinase
  • Known blood dyscrasias or significant gastrointestinal disease
  • Pregnant and lactating women
  • Known hypersensitivity to colchicine
  • Current treatment with colchicine for any indications
  • Emergency surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT03015831

Contact: Ramzi Tabbalat, MD, FACC 00962795535522

Istishari Hospital Not yet recruiting
Amman, Jordan
Contact: Ayman Hammoudeh, MD, FACC    0096265001000      
Khalidi Hospital & Medical Center Not yet recruiting
Amman, Jordan
Contact: Ramzi Tabbalat, MD, FACC         
Sponsors and Collaborators
Jordan Collaborating Cardiology Group
Principal Investigator: Ramzi Tabbalat, MD, FACC JCC Group, Cardiology Department, Khalidi Medical Center, Amman, Jordan
  More Information

Responsible Party: Jordan Collaborating Cardiology Group Identifier: NCT03015831     History of Changes
Other Study ID Numbers: JordanCCG
Study First Received: January 4, 2017
Last Updated: January 7, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Our Group's website will share data. Researchgate will share data. Eventual results will be announced to medical community through local presentations, and international congresses and publications.

Keywords provided by Jordan Collaborating Cardiology Group:
Atrial fibrillation
Cardiac surgery

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Gout Suppressants
Antirheumatic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents processed this record on September 21, 2017